Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis

被引：0
|
作者：
Knowles, Susan [1 ]
Taroumian, Sara [1 ]
Lisse, Jeffrey R. [1 ]
Yanes, James [1 ]
Ampel, Neil M. [2 ]
Gall, Eric P. [3 ]
Grau, Rafael G. [1 ]
Bode, Barbara Y. [2 ]
Vaz, Berchman A. [4 ]
Galgiani, John [5 ]
Hoover, Susan E. [1 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] So AZ VA Med Ctr, Tucson, AZ USA
[3] Arizona Arthrit Ctr, Tucson, AZ USA
[4] Catalina Pointe Arthrit & Rheumatol, Tucson, AZ USA
[5] Valley Fever Ctr Excellence, Tucson, AZ USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2466
引用
收藏
页码：S961 / S961
页数：1
相关论文
共 50 条
  • [31] Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia
    Machado-Alba, J. E.
    Ruiz, A. F.
    Machado-Duque, M. E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (06) : 506 - 511
  • [32] Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Cho, Soo-Kyung
    Kim, Hyoungyoung
    Song, Yeo-Jin
    Kim, Hye Won
    Nam, Eunwoo
    Lee, Shin-Seok
    Lee, Hye-Soon
    Park, Sung-Hoon
    Lee, Yeon-Ah
    Park, Min-Chan
    Chang, Sung Hae
    Kim, Hyoun-Ah
    Kwok, Seung-Ki
    Kim, Hae-Rim
    Kim, Hyun-Sook
    Yoon, Bo Young
    Uhm, Wan-Sik
    Kim, Yong-Gil
    Kim, Jae Hoon
    Lee, Jisoo
    Choi, Jeongim
    Sung, Yoon-Kyoung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (04): : 546 - +
  • [33] FACTORS ASSOCIATED WITH INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hammou, O.
    Chennouf, F.
    Azzouzi, H.
    Linda, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1441 - 1441
  • [34] TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR
    Joanna, Kedra
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1147 - 1148
  • [35] Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis
    Wendling, Daniel
    Goupille, Philippe
    IMMUNOTHERAPY, 2020, 12 (12) : 857 - 860
  • [36] Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
    Razak, Salmi Abdul
    Bakry, Mohd Makmor
    Said, Mohd Shahrir Mohamed
    Tan, Chai-Eng
    Redzuan, Adyani Md
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [37] Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR
    Kedra, Joanna
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    JOINT BONE SPINE, 2021, 88 (01)
  • [38] Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children
    Cron, Randy Q.
    CURRENT OPINION IN RHEUMATOLOGY, 2022, 34 (05) : 274 - 279
  • [39] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [40] An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
    So, Anthony
    Inman, Robert Davies
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (03): : 453 - 471
12345